All In Biotech

Drug Trial Radar · NCT02230228

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Apr 2014

Primary completion

Sep 2014

Study completion Feb 2015

Sponsor

Lead sponsor
Alkeus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.

Conditions

  • Stargardt Disease
  • Age-related Macular Degeneration
  • Other Retinal Dystrophies

Interventions

  • ALK-001 (No generic name)Drug

    Daily, oral administration of ALK-001 capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of 4-week daily dosing of ALK-001 in healthy adults.Time frame: 4 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.